RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.
With that in mind, we can’t wait to bring the community together, face-to-face, for the first annual RNA Leaders World Congress.
So, if you’re passionate about all things RNA do join us, and more than 150 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders World Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.
“We still have work to do, but the future is bright for RNA therapies.”
Lorna Harries, CSO, Senisca
500+ companies actively developing RNA therapeutics
4000+ live clinical trials for RNA therapeutics and vaccines
2 major mRNA vaccine approvals in 2020
3 RNAi therapeutic approvals in the past 4 years
1500+ investors actively looking to fund RNA technology
96 successful fund raises by mid 2021 (vs 101 total in 2020)
More than $1.65bn raised by RNA biotech mid 2021
Millions of lives saved by mRNA vaccines to date
Do you offer products or services to support RNA drug development? The pharma and biotech executives attending RNA Leaders World Congress want to meet you! They are looking for: